Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition
Galderma Group AG has proposed two new board members and announced that CFO Luigi La Corte will step down to pursue a new opportunity.
Stocks · News reference
Galderma Group AG's Chief Financial Officer, Luigi La Corte, has been appointed as the new finance chief at Novo.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Galderma Group AG has proposed two new board members and announced that CFO Luigi La Corte will step down to pursue a new opportunity.
The German Federal Cartel Office (Bundeskartellamt) has listed a merger control proceeding regarding Galderma Group AG's acquisition of ZO Skin Health.
J.P. Morgan analysts issued a research note maintaining an overweight rating on Galderma, citing strong growth prospects driven by the Nemluvio drug and the acquisition of ZO Skin Health.
Galderma has introduced an enhanced version of its ALASTIN Restorative Eye Complex, featuring the proprietary TriHex+ platform to address signs of aging around the eye area.
Investment bank Berenberg increased its price target for Galderma Group AG, citing third-quarter financial results that exceeded market expectations.
Galderma has received regulatory approval from China's National Medical Products Administration (NMPA) for Relfydess to treat moderate-to-severe frown lines in adults.